Deciphering Fc-effector functions against SARS-CoV-2
- PMID: 38365562
- DOI: 10.1016/j.tim.2024.01.005
Deciphering Fc-effector functions against SARS-CoV-2
Abstract
Major efforts were deployed to study the antibody response against SARS-CoV-2. Antibodies neutralizing SARS-CoV-2 have been extensively studied in the context of infections, vaccinations, and breakthrough infections. Antibodies, however, are pleiotropic proteins that have many functions in addition to neutralization. These include Fc-effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Although important to combat viral infections, these Fc-effector functions were less studied in the context of SARS-CoV-2 compared with binding and neutralization. This is partly due to the difficulty in developing reliable assays to measure Fc-effector functions compared to antibody binding and neutralization. Multiple assays have now been developed and can be used to measure different Fc-effector functions. Here, we review these assays and what is known regarding anti-SARS-CoV-2 Fc-effector functions. Overall, this review summarizes and updates our current state of knowledge regarding anti-SARS-CoV-2 Fc-effector functions.
Keywords: ADCC; ADCP; Fc-effector functions; SARS-CoV-2; antibody.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Similar articles
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.Front Immunol. 2023 Aug 3;14:1231276. doi: 10.3389/fimmu.2023.1231276. eCollection 2023. Front Immunol. 2023. PMID: 37600825 Free PMC article.
-
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern.Front Immunol. 2025 May 20;16:1571835. doi: 10.3389/fimmu.2025.1571835. eCollection 2025. Front Immunol. 2025. PMID: 40463385 Free PMC article.
-
SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.J Med Virol. 2024 Mar;96(3):e29527. doi: 10.1002/jmv.29527. J Med Virol. 2024. PMID: 38511514
-
Research progress in Fc-effector functions against SARS-CoV-2.J Med Virol. 2024 May;96(5):e29638. doi: 10.1002/jmv.29638. J Med Virol. 2024. PMID: 38682662 Review.
-
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies.Trends Immunol. 2024 Aug;45(8):609-624. doi: 10.1016/j.it.2024.06.003. Epub 2024 Jul 20. Trends Immunol. 2024. PMID: 39034185 Review.
Cited by
-
Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages.Nat Commun. 2024 Dec 30;15(1):10764. doi: 10.1038/s41467-024-54458-w. Nat Commun. 2024. PMID: 39737903 Free PMC article.
-
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Wellcome Open Res. 2024 Dec 2;8:350. doi: 10.12688/wellcomeopenres.19414.2. eCollection 2023. Wellcome Open Res. 2024. PMID: 39640868 Free PMC article.
-
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters.J Transl Med. 2025 Jul 11;23(1):783. doi: 10.1186/s12967-025-06837-0. J Transl Med. 2025. PMID: 40646552 Free PMC article.
-
Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.Virology. 2025 Apr;605:110467. doi: 10.1016/j.virol.2025.110467. Epub 2025 Feb 25. Virology. 2025. PMID: 40037139
-
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice.NPJ Vaccines. 2025 Jan 13;10(1):7. doi: 10.1038/s41541-025-01066-4. NPJ Vaccines. 2025. PMID: 39805865 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous